Prospects of laboratory risk evaluation of multiple sclerosis relapse and progressing

Prospects of laboratory risk evaluation of multiple sclerosis relapse and progressing

The Relapsing-Remitting Multiple Sclerosis (MS) patients research has revealed that the matrix metalloproteinase-2 level in cerebrospinal fluid which is higher then 30 ng/ml during the relapse and/or remission period increases repeated relapse risk during 2 years term by 2.8 times. The rapid MS prog...

Full description

Bibliographic Details
Main Authors: I. V. Smagina, S. A. Yelchaninova, A. V. Popovtseva, Yu. N. Ignatova, A. O. Gridina, A. S. Fedyanin
Format: Article
Language:English
Published: Siberian State Medical University (Tomsk) 2010-08-01
Series:Bûlleten' Sibirskoj Mediciny
Subjects:
multiple sclerosis
cerebrospinal fluid
Online Access:https://bulletin.tomsk.ru/jour/article/view/1646
id doaj-df47fe7c7fc74ac2969997274c25017a
record_format Article
spelling doaj-df47fe7c7fc74ac2969997274c25017a2021-07-29T08:37:52ZengSiberian State Medical University (Tomsk)Bûlleten' Sibirskoj Mediciny1682-03631819-36842010-08-019415215510.20538/1682-0363-2010-4-152-1551148Prospects of laboratory risk evaluation of multiple sclerosis relapse and progressingI. V. Smagina0S. A. Yelchaninova1A. V. Popovtseva2Yu. N. Ignatova3A. O. Gridina4A. S. Fedyanin5ГУЗ «Краевая клиническая больница»Алтайский государственный медицинский университетАлтайский государственный медицинский университетГУЗ «Краевая клиническая больница»ГУЗ «Краевая клиническая больница»ГУЗ «Краевая клиническая больница»The Relapsing-Remitting Multiple Sclerosis (MS) patients research has revealed that the matrix metalloproteinase-2 level in cerebrospinal fluid which is higher then 30 ng/ml during the relapse and/or remission period increases repeated relapse risk during 2 years term by 2.8 times. The rapid MS progressing is associated with the high level of adhesion molecule (sPECAM) in cerebrospinal fluid.https://bulletin.tomsk.ru/jour/article/view/1646multiple sclerosiscerebrospinal fluid
collection DOAJ
language English
format Article
sources DOAJ
author I. V. Smagina
S. A. Yelchaninova
A. V. Popovtseva
Yu. N. Ignatova
A. O. Gridina
A. S. Fedyanin
spellingShingle I. V. Smagina
S. A. Yelchaninova
A. V. Popovtseva
Yu. N. Ignatova
A. O. Gridina
A. S. Fedyanin
Prospects of laboratory risk evaluation of multiple sclerosis relapse and progressing
Bûlleten' Sibirskoj Mediciny
multiple sclerosis
cerebrospinal fluid
author_facet I. V. Smagina
S. A. Yelchaninova
A. V. Popovtseva
Yu. N. Ignatova
A. O. Gridina
A. S. Fedyanin
author_sort I. V. Smagina
title Prospects of laboratory risk evaluation of multiple sclerosis relapse and progressing
title_short Prospects of laboratory risk evaluation of multiple sclerosis relapse and progressing
title_full Prospects of laboratory risk evaluation of multiple sclerosis relapse and progressing
title_fullStr Prospects of laboratory risk evaluation of multiple sclerosis relapse and progressing
title_full_unstemmed Prospects of laboratory risk evaluation of multiple sclerosis relapse and progressing
title_sort prospects of laboratory risk evaluation of multiple sclerosis relapse and progressing
publisher Siberian State Medical University (Tomsk)
series Bûlleten' Sibirskoj Mediciny
issn 1682-0363
1819-3684
publishDate 2010-08-01
description The Relapsing-Remitting Multiple Sclerosis (MS) patients research has revealed that the matrix metalloproteinase-2 level in cerebrospinal fluid which is higher then 30 ng/ml during the relapse and/or remission period increases repeated relapse risk during 2 years term by 2.8 times. The rapid MS progressing is associated with the high level of adhesion molecule (sPECAM) in cerebrospinal fluid.
topic multiple sclerosis
cerebrospinal fluid
url https://bulletin.tomsk.ru/jour/article/view/1646
work_keys_str_mv AT ivsmagina prospectsoflaboratoryriskevaluationofmultiplesclerosisrelapseandprogressing
AT sayelchaninova prospectsoflaboratoryriskevaluationofmultiplesclerosisrelapseandprogressing
AT avpopovtseva prospectsoflaboratoryriskevaluationofmultiplesclerosisrelapseandprogressing
AT yunignatova prospectsoflaboratoryriskevaluationofmultiplesclerosisrelapseandprogressing
AT aogridina prospectsoflaboratoryriskevaluationofmultiplesclerosisrelapseandprogressing
AT asfedyanin prospectsoflaboratoryriskevaluationofmultiplesclerosisrelapseandprogressing
_version_ 1721253753286295552

Similar Items